Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma

Gynecologic Oncology

Volumn 93, Issue 2, 2004, Pages 301-306

  Leitao, Mario M ^a   Soslow, Robert A ^a   Baergen, Rebecca N ^b   Olvera, Narciso ^a   Arroyo, Crispinita ^a   Boyd, Jeff ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Early stage; Ovarian cancer; p53; TP53; Tumor suppressor gene

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER STAGING; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; EXON; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; STATISTICAL SIGNIFICANCE;

EPITHELIAL CELLS; FEMALE; FRAMESHIFT MUTATION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION, MISSENSE; NEOPLASM STAGING; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1942509342     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.01.043     Document Type: Article

References (16)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics, 2003. CA Cancer J. Clin. 53:2003;5-26.
2. Ozols R.F., Rubin S.C., Thomas G.M., Robboy S.J. Epithelial ovarian cancer. Hoskins W.J., Perez C.A., Young R.C. Principles and Practice of Gynecologic Oncology. Third ed. 2000;981-1058 Lippincott, Williams and Wilkins, Philadelphia.
3. Rosenthal A., Jacobs I. Ovarian cancer screening. Semin. Oncol. 25:1998;315-325.
4. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
5. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
6. Oren M. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274:1999;36031-36034.
7. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
8. Casey G., Lopez M.E., Ramos J.C., Plummer S.J., Arboleda M.J., Shaughnessy M.et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 13:1996;1971-1981.
9. Boyd J., Hamilton T.C., Berchuck A. Oncogenes and tumor-suppressor genes. Hoskins W.J., Perez C.A., Young R.C. Principles and Practice of Gynecologic Oncology. Third ed. 2000;103-128 Lippincott, Williams and Wilkins, Philadelphia.
10. Kmet L.M., Cook L.S., Magliocco A.M. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer. 97:2003;389-404.
11. Bonsing B.A., Corver W.E., Gorsira M.C., van Vliet M., Oud P.S., Cornelisse C.J.et al. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry. Cytometry. 28:1997;11-24.
12. Hernandez-Boussard T., Rodriguez-Tome P., Montesano R., Hainaut P. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum. Mutat. 14:1999;1-8.
13. Soussi T., Dehouche K., Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum. Mutat. 15:2000;105-113.
14. Leitao M.M., Boyd J., Hummer A., Olvera N., Arroyo C.D., Venkatraman E.et al. Clinicopathologic analysis of early-stage sporadic epithelial ovarian carcinoma. Am. J. Surg. Pathol. 28:2004;147-159.
15. Russell P. Surface epithelial-stromal tumors of the ovary. Kurman R.J. Blaustein's Pathology of the Female Genital Tract. Fourth ed. 1994;705-782 Springer-Verlag, New York.
16. Schwartz D.R., Kardia S.L., Shedden K.A., Kuick R., Michailidis G., Taylor J.M.et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 62:2002;4722-4729.